Mutational testing is an integral part of the management of myeloproliferative neoplasms (MPNs), as results from this assessment can both guide treatment selection and provide prognostic information. In this article, Dr. Aaron Gerds discusses best practice regarding the utility of mutational testing in clinical practice when treating patients with MPNs.

Approaching management and diagnosis of a patient with polycythemia vera (PV) can be challenging. In this activity, Dr. Rampal explains the goals of therapy, prognostication of thrombosis, and therapies in first-line treatment. He also discusses the patient-related features to consider when developing a treatment plan.

Management of myeloproliferative neoplasms has evolved considerably since the identification of JAK2 and targeted therapy that has improved disease-related symptoms and quality of life. Our renowned faculty will provide updates in the latest data related to diagnosis, treatment options, guidelines, and standards of care through a highly interactive educational experience. Three real-life case scenarios will be presented, and the faculty will discuss treatment options and the journey of each patient.

This activity was previously presented as a webinar with live Q&A in September of 2020. Please note: If you participated in the live webinar, you are ineligible to receive an additional 1.25 contact hours of credit and may not re-submit for credit previously awarded.

It is well known that JAK/STAT signaling plays a central role in the pathogenesis of myelofibrosis (MF), and the demonstrated efficacy of the JAK inhibitor ruxolitinib in myelofibrosis has established it as standard of care in intermediate- and high-risk disease. Based on the success of ruxolitinib in this setting, other JAK inhibitors have been under investigation to further improve clinical outcomes in MF. The recent approval of fedratinib in both the frontline and second-line setting has expanded treatment options for MF, and pacritinib and momelotinib are also showing great promise in clinical trials. In this article, Dr. Elizabeth Hexner will review recent data supporting the role of JAK inhibitors for the treatment of MF.

The approval of ruxolitinib established JAK inhibitor therapy as the standard of care for intermediate- and high-risk myelofibrosis (MF), and the recent approval of fedratinib further supports the important role of JAK inhibitors in this setting. There is an urgent need for novel targeted therapies and new approaches. This article summarizes some of the most compelling data from key clinical trials investigating novel treatment approaches for MF and concludes with strategies to improve physician-patient communication.

Today, nurses assume more and more responsibility for educating patients/families and helping them become responsible for their own health status. To help nurses provide optimal care and education for patients with myelofibrosis (MF), they require education that helps them assimilate a knowledge of the disease pathology and current and emerging treatments. In this activity, Sara Tinsley, PhD, APRN, AOCN®, will provide considerations for adverse events/key safety issues, as well as monitoring and management of treatment-associated adverse events, with strategies and tools for patient/family communication, education, and engagement.

This activity was previously presented as a webinar with live Q&A in May of 2020. Please note: If you participated in the live webinar, you are ineligible to receive an additional 1.0 contact hour of credit and may not re-submit for credit previously awarded.

The community multidisciplinary healthcare provider seeking to improve competence and confidence in the utilization of approved JAK inhibitor therapy and increase their knowledge of emerging treatment options will benefit from this expert review of key data in myelofibrosis from 2019 by Drs. Bose and Mesa. Participants will also be enlightened by how this data can impact their current practice and gain confidence in their ability to communicate with patients to ensure they make informed treatment decisions.

This activity was previously presented as a webinar with live Q&A in January of 2020. Please note: If you participated in the live webinar, you are ineligible to receive an additional 1.0 contact hour of credit and may not re-submit for credit previously awarded.

As outcomes for myelofibrosis patients remain suboptimal and treatment options are limited, it is important now more than ever for clinicians to keep abreast of the potential and emerging treatment options. This collaborative peer-to-peer exchange will draw on the collective experience of our three leading experts in research and treatment of patients with myelofibrosis. This activity focuses on the current, newly approved, and emerging JAK inhibitors, including sharing best practices and emerging data from clinical trials.

This activity was previously presented on September 13, 2019 to a live audience during the SOHO 2019 Annual Meeting in Houston, Texas. Please note: If you attended the live meeting or simulcast viewing, you are ineligible to receive an additional 1.0 contact hour of credit and may not re-submit for credit previously awarded.